Telomeres are short in type II alveolar epithelial cells (AECs) of patients with idiopathic pulmonary fibrosis (IPF). Whether dysfunctional telomeres contribute directly to development of lung fibrosis remains unknown. The objective of this study was to investigate whether telomere dysfunction in type II AECs, mediated by deletion of the telomere shelterin protein TRF1, leads to pulmonary fibrosis in mice (SPC-Cre TRF1 fl/fl mice). Deletion of TRF1 in type II AECs for 2 weeks increased gH2AX DNA damage foci, but not histopathologic changes in the lung. Deletion of TRF1 in type II AECs for up to 9 months resulted in short telomeres and lung remodeling characterized by increased numbers of type II AECs, a-smooth muscle actin + mesenchymal cells, collagen deposition, and accumulation of senescence-associated b-galactosidase + lung epithelial cells. Deletion of TRF1 in collagen-expressing cells caused pulmonary edema, but not fibrosis. These results demonstrate that prolonged telomere dysfunction in type II AECs, but not collagen-expressing cells, leads to age-dependent lung remodeling and fibrosis. We conclude that telomere dysfunction in type II AECs is sufficient to cause lung fibrosis, and may be a dominant molecular defect causing IPF. SPC-Cre TRF1 fl/fl mice will be useful for assessing cellular and molecular mechanisms of lung fibrosis mediated by telomere dysfunction.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a terminal, age-associated, interstitial lung disease (ILD) with an overall prevalence of 14 to 43 per 100,000 people (1) . Consistent with the association with aging, telomere dysfunction has been implicated in the pathogenesis of IPF (2, 3) . Evidence includes the observation that telomeres are short in type II alveolar epithelial cells (AECs) of IPF patients (4, 5) , that type II AEC expression of senescence markers is unique to IPF lungs (6) , and that peripheral blood leukocyte telomere length predicts survival in IPF patients (7) . Variants in genes regulating telomere length including telomerase reverse transcriptase (TERT), RNA component of telomerase (TERC), and oligosaccharide-binding fold containing 1 (OBFC1) genes have been identified as susceptibility loci for development of sporadic IPF (8) . Similarly, mutations in TERT, TERC, regulator of telomere elongation helicase 1 (RTEL1), and poly(A)-specific ribonuclease (PARN), have been identified in kindreds of familial pulmonary fibrosis (4, (9) (10) (11) . Pulmonary fibrosis is also found in a subset of patients with dyskeratosis congenita (DKC), a disease of telomere dysfunction (12, 13) . Although these studies implicate telomere dysfunction in the development of pulmonary fibrosis, evidence that telomere dysfunction contributes directly to the development of lung fibrosis is lacking.
Telomeres consist of tandem TTAGGG repeats and associated proteins (shelterin complex) that form a capping structure at the ends of chromosomes, which protects them from degradation and activation of DNA repair responses (14) . Telomeres shorten with each cell division. When critically shortened, cells senesce due to uncapping of telomeres and activation of cell-cycle arrest programming. Modeling the biological consequences of telomere shortening in mice has been limited because murine telomeres are 5-10 times longer and their lifespan 30 times shorter than those in humans (15) . One approach for studying telomere biology in vivo has been to conditionally delete proteins of the shelterin complex, leading to the uncapping of telomeres. When shelterin complex proteins are deleted from specific cell types, phenotypes consistent with dysfunctional telomeres manifest (16) (17) (18) . The experiments Telomeres are short in type II alveolar epithelial cells (AECs) of patients with idiopathic pulmonary fibrosis (IPF). Whether dysfunctional telomeres contribute directly to development of lung fibrosis remains unknown. The objective of this study was to investigate whether telomere dysfunction in type II AECs, mediated by deletion of the telomere shelterin protein TRF1, leads to pulmonary fibrosis in mice (SPC-Cre TRF1 fl/fl mice). Deletion of TRF1 in type II AECs for 2 weeks increased γH2AX DNA damage foci, but not histopathologic changes in the lung. Deletion of TRF1 in type II AECs for up to 9 months resulted in short telomeres and lung remodeling characterized by increased numbers of type II AECs, α-smooth muscle actin + mesenchymal cells, collagen deposition, and accumulation of senescence-associated β-galactosidase + lung epithelial cells. Deletion of TRF1 in collagen-expressing cells caused pulmonary edema, but not fibrosis. These results demonstrate that prolonged telomere dysfunction in type II AECs, but not collagen-expressing cells, leads to age-dependent lung remodeling and fibrosis. We conclude that telomere dysfunction in type II AECs is sufficient to cause lung fibrosis, and may be a dominant molecular defect causing IPF.
SPC-Cre TRF1
fl/fl mice will be useful for assessing cellular and molecular mechanisms of lung fibrosis mediated by telomere dysfunction.
reported in this study adopt these approaches by conditionally deleting telomere repeat binding factor 1 (TRF1) in type II AECs or collagen-expressing cells to examine the consequence of dysfunctional telomeres in resident lung cells.
Results
Telomere dysfunction in AECs. To examine the consequences of type II AEC-specific telomere dysfunction, we adapted approaches used to study telomere dysfunction in keratinocytes and leukocytes (16, 17) and crossed TRF1 fl/fl mice with mice capable of inducibly expressing Cre recombinase in surfactant protein Cexpressing cells (SPC-Cre ER T2 rtTA mice, which contain tamoxifen-inducible Cre-modified estrogen receptor fusion protein) to generate SPC-Cre TRF1 fl/fl mice (19) . Following intraperitoneal tamoxifen injections, deletion of TRF1 was confirmed by immunoblot in type II AECs isolated from SPC-Cre TRF1 fl/fl mice ( Figure 1A ). Lungs of SPC-Cre TRF1 fl/fl mice treated with weekly tamoxifen injections for 2 weeks were histopathologically normal (Figure 2 , B and F, and Supplemental Figure 1B ; supplemental material available online with this article; doi:10.1172/jci.insight.86704DS1) but had higher mortality following intranasal infection with influenza virus (A/PR/8/34) compared with tamoxifen-treated TRF1 fl/fl mice ( Figure 1B ), indicating worse inflammatory lung injury in mice with type II AEC telomere dysfunction. At this time point, in the absence of influenza viral infection, lungs of SPC-Cre TRF1 fl/fl mice had increased γH2AX foci in type II AECs ( Figure 1D ), consistent with the uncapping of telomeres in these cells. Quantification revealed that 45% of total SPC-positive cells were also γH2AX positive ( Figure 1E) .
Deletion of TRF1 in lung epithelial cells leads to the development of lung fibrosis. When mice were treated with weekly injections of tamoxifen for up to 9 months, it was found that SPC-Cre TRF1 fl/fl mice have worse survival than tamoxifen-treated TRF1 fl/fl control mice. Mice began to die 6 months after tamoxifen administration and no mice survived longer than 9 months of weekly tamoxifen treatments ( Figure  1C ). To determine why SPC-Cre TRF1 fl/fl mice had impaired survival, the lungs of SPC-Cre TRF1 fl/fl mice and TRF1 fl/fl control mice were studied following 3 months of weekly tamoxifen injections or when moribund (following 6-9 months of weekly tamoxifen injections). SPC-Cre TRF1 fl/fl mice challenged with tamoxifen for 3 months showed subtle areas of lung remodeling, with scattered areas of septal thickening (Figure 2 , C and G, and Supplemental Figure 1C ). In contrast, SPC-Cre TRF1 fl/fl mice that Figure 1A ). When extent of lung fibrosis was scored in a blinded manner using the Ashcroft scale (20) , the SPC-Cre TRF1 fl/fl mice receiving tamoxifen for 8 months had a significantly higher score compared with SPC-Cre TRF1 fl/fl mice treated with tamoxifen for 3 months or TRF1 fl/fl controls ( Figure 2I ). Furthermore, the levels of hydroxyproline ( Figure 2J ) and active TGF-β1 ( Figure 2K ), were elevated in lungs of terminal SPC-Cre TRF1 fl/fl mice compared with TRF1 fl/fl control lungs. Analysis of bronchoalveolar lavage (BAL) fluid cell counts and differentials revealed increased numbers of mononuclear cells ( Figure 3A ) and slight increases in neutrophils ( Figure 3B ) and lymphocytes ( Figure 3C Table 2 ). Weekly tamoxifen treatment of TRF1 fl/fl control mice and the surviving Col1a2-Cre TRF1 fl/fl mice for up to 6 months did not result in lung remodeling or fibrosis (Figure 4 , F and G). These findings suggest that maintaining normal telomere function in lung mesenchymal cells is critical to preserving the lung barrier and that telomere dysfunction leading to lung fibrosis may be specific to type II AECs and not simply a consequence of telomere dysfunction within any resident lung cell. Figure 5B 
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Discussion
Molecular defects in IPF type II AECs include short telomeres (4, 5) and expression of molecular markers of senescence (6, 26) . The findings summarized above show that telomere dysfunction isolated to type II AECs leads to the development of lung remodeling and fibrosis. This lung remodeling evolves as the mice age and is not preceded by histopathologic evidence of lung injury or type II AEC depletion, although there was evidence for activation of a DNA damage response in these cells. Nevertheless, despite histopathologically normal lungs, SPC-Cre TRF1 fl/fl mice are more susceptible to influenza A infection, indicating that telomere Telomere uncapping leads to cellular senescence (27, 28) . Consistent with these reports, our studies show increased numbers of senescent type II AECs in SPC-Cre TRF1 fl/fl mice. Accumulation of senescent type II AECs contributes to the type II AEC hyperplasia observed in SPC-Cre TRF1 fl/fl mice at the 8-month time point. In addition, we observed senescent type II AEC accumulation in the areas of fibrosis, which was not evident at the 2-week or 3-month time point when no major lung remodeling was present. The accumulation of senescent cells correlated temporally to the development of lung fibrosis, suggesting that they may contribute to the fibrotic process. Conditional deletion of shelterin proteins has enabled study of the consequences of telomere dysfunction in the skin (17) , bone marrow (16), and lung (18, 23) . These models have recapitulated features of telomere-mediated disease. For example, deletion of TRF1 from keratinocytes or hematopoietic cells leads to hyperkeratosis or bone marrow failure, respectively (16, 17) . Within lung, we show that telomere dysfunction and shortening isolated to type II AECs leads to spontaneous lung remodeling and fibrosis. The lung fibrosis mediated by telomere dysfunction appears to be selective to type II AECs, as telomere dysfunction in collagen-expressing cells did not produce lung fibrosis. In contrast, induction of telomere dysfunction by uncapping telomeres in collagen-expressing cells caused pulmonary edema without evidence for pathological abnormalities in other tissues such as skin, liver, spleen, and kidney. These findings suggest that lung edema might have stemmed from dysfunctional lung fibroblasts or pericytes that are required to maintain the barrier in the lung. Overall, these findings suggest that the organ-specific manifestations of telomere dysfunction may be due to telomere dysfunction in a specific cell subtype within that organ. In the case of lung fibrosis, the relevant cell is the type II AEC. slow turnover of type II AECs, these data show that it takes up to 8 months to develop short telomeres in type II AECs following deletion of TRF1. Collectively, our findings show that type II AEC telomere dysfunction and shortening, in the absence of lung injury, may be sufficient to cause lung fibrosis.
Histopathologic evidence of lung fibrosis in SPC-Cre TRF1 fl/fl mice was identified months after deletion of TRF1, which led to the uncapping of telomeres and activation of a DNA damage response. This finding is consistent with reports that pulmonary fibrosis in patients with TERT or TERC mutations typically develops at age 50 or greater, despite carrying the mutation from birth, and having short telomeres since childhood (29) . Why there is a relative delay in developing fibrosis in patients or our model remains unresolved. One possibility is that although senescent type II AECs are detectable at the time of uncapping telomeres, they may need to accumulate to a critical mass such that the profibrotic mediators they release have the highest activity. Another possibility is that senescence reprogramming of cells alters their phenotype over time (30) and that it takes time for the senescent cells to develop a profibrotic phenotype. A third possibility is that the profibrotic phenotype of type II AECs is related to critically short telomeres, which requires more than 3 months to develop in SPC-Cre TRF1 fl/fl mice. Finally, although the SPC-Cre TRF1 fl/fl mice were housed in a barrier facility, it is possible that unrecognized environmental exposures interact with telomere shortening in type II AECs to cause lung fibrosis. Which of these (or other) mechanisms are at play in this model or IPF will require additional studies to resolve.
SPC-Cre TRF1 fl/fl mice provide a potentially novel in vivo model of lung remodeling and fibrosis. The SPC-Cre TRF1
fl/fl mouse model of fibrosis recapitulates many pathologic findings in IPF including short telomeres in type II AECs (4, 25) , accumulation of senescent type II AECs (6, 26) , type II AEC hyperplasia (3), increased burden of alveolar macrophages (25) , accumulation of α-SMA-immunoreactive mesenchymal cells (24, 31) , elevated levels of active TGF-β1 (32) , and lung fibrosis (3) . In addition to recapitulating features of IPF, the SPC-Cre TRF1
fl/fl mouse model of fibrosis has advantages over the commonly used bleomycin model of lung fibrosis. Most notable are that fibrosis occurs spontaneously and progresses to death of all mice over months, a time interval more consistent with fibrosis progression in IPF patients. In contrast, the lung fibrosis in the bleomycin model is not progressive and is mediated by acute lung injury induced by intra-alveolar instillation of a chemotherapeutic compound. Although SPC-Cre TRF1 fl/fl mice do not manifest all pathologic features of IPF (e.g., fibroblast foci were not identified) the findings in SPC-Cre TRF1 fl/fl mice suggest that IPF may be mediated by telomere dysfunction in type II AECs and that the progressive terminal course of IPF is due to irreversible telomere shortening in type II AECs. SPC-Cre TRF1 fl/fl mice should be useful to study this possibility and identify key cellular and molecular mechanisms of lung fibrosis mediated by telomere dysfunction in IPF type II AECs. Hydroxyproline assay. Hydroxyproline levels were quantified as described previously (33) . Murine lungs were homogenized in 1 ml water. One hundred and twenty-five microliters of 50% trichloroacetic acid was added and the suspension incubated on ice for 20 minutes. Samples were centrifuged at 800 g for 5 minutes at 4°C. The supernatant was discarded and 1 ml of 12N HCl added to the pellet, which was then baked in an oven at 110°C for 24 hours. Dried pellets were reconstituted in 2 ml distilled water. Sample or serially diluted 6-hydroxyproline standard (200 μl) was added to chloramine T (1.4% chloramine T in 0.5 M Na acetate and 10% isopropanol) and incubated at room temperature for 20 minutes. Five hundred microliters of Ehrlich's solution (1 M p-dimethylaminobenzaldehyde [p-DMBA] in 70% isopropanol and 30% perchloric acid] was added and the mixture incubated at 65°C for 15 minutes and absorbance measured on a spectrophotometer at 550 nm.
Methods
Histopathology and immunofluorescence staining. Lungs were perfused with 10% formalin to an inflation pressure of 20 cm H 2 O and fixed overnight before embedding in paraffin and sectioning at 4-μm thickness. For histopathology, tissues were stained with H&E or Masson's trichrome. For immunohistochemistry, tissues were deparaffinized in xylene, rehydrated in an ethanol gradient, permeabilized with 0.1 % Triton X-100, and antigen retrieved by heating at 95°C for 20 minutes in 10 mM sodium citrate buffer, pH 6.0. Sections were blocked (3% BSA, 10% goat serum, PBS) and incubated with primary antibodies (SPC 1:300 dilution, SMA 1:75 dilution, and γH2AX 1:500 dilution) overnight at 4°C. Tissues were washed thrice and incubated with appropriate secondary antibodies at 20°C, washed, and mounted using Prolong Gold Antifade Mounting Medium with DAPI (Life Technologies). Images were acquired on a Leica confocal microscope.
Telomere Q-FISH assay. Telomere lengths were measured on paraffin-embedded tissue sections by Q-FISH (34) . Briefly, after deparaffinization, tissues underwent antigen retrieval by heating in a microwave in 10 mM sodium citrate buffer, pH 6.5, then incubating for 15 minutes in 0.01 M HCL containing 1% pepsin (Thermo Fisher Scientific). The tissues were washed and air-dried before treating with 10 mg/ml RNase solution (QIAGEN). After washing again, the tissues were incubated with 0.3 μg/ml PNA FISH probe TelC-Cy3 (Panagene) suspended in 70% formamide, 30% water, and 10 mM Tris, pH 7.5, heated at 78°C for 10 minutes, and then left overnight at room temperature. The tissues were then washed sequentially with formamide buffer and then PBS containing 0.1% Tween, blocked with 3% BSA (Sigma-Aldrich) and 10% donkey serum, and incubated overnight at 4°C with goat anti-SPC antibody. Tissues were washed with PBS containing 0.1% Tween and incubated with donkey anti-goat Alexa 488 secondary antibody at 20°C for 1 hour, washed, and mounted using Prolong Gold Antifade Mounting Medium with DAPI. Images were acquired using a Zeiss Axio Imager 2 microscope and telomere signal intensity quantified using MetaMorph imaging analysis software (Molecular Devices).
Immunophenotyping by flow cytometry. Murine lungs were digested in 10 mg/ml Dispase (Life Technologies, catalog 17105-041) for 1 hour and suspended in DMEM containing 10% FBS and DNase I. Cell suspensions were serially filtered through 70-μm and 40-μm filters. Fluorescence-conjugated antibodies were incubated in blocking buffer containing 1% BSA for 30 minutes at 4°C. In some groups, cells were fixed and permeabilized with Cytofix/Cytoperm according to the manufacturer's protocol (BD Biosciences). Cells were then stained with fluorescein-conjugated rabbit anti-collagen type I antibody (Rockland Immunochemicals) in Cytoperm wash buffer for 30 minutes at 4°C. After washing, cells were suspended in buffer containing 1% BSA and analyzed on an LSR II flow cytometer (BD Biosciences) and acquired data were analyzed using the integrated FlowJO software v10.
BAL fluid collection. BAL fluid was collected from euthanized mice by lavaging lungs with 1 ml PBS. Recovered BAL fluid was centrifuged at 800 g for 5 minutes at 4°C and the supernatant recovered for analysis. Red blood cells were lysed in the cell pellet with ammonium chloride-potassium (ACK) buffer and the cells recentrifuged and then suspended in 1 ml PBS. The total numbers of cells were counted using a hemocytometer. Cells were cytospun and cell differentials determined by modified Giemsa stain (Electron Microscopy Sciences).
Enzyme-linked immunosorbent assay. BAL fluid supernatant was used to determine active TGF-β1 levels according to the manufacturer's instructions (Biolegend, catalog 437707).
Isolation of murine AECs. Lungs from tamoxifen-treated SPC-Cre TRF1 fl/fl mice and age-matched TRF1 fl/fl controls were serially lavaged with PBS and then perfused via the pulmonary artery with PBS containing 0.5 % EDTA. Lungs were digested in 10 mg/ml Dispase suspended in DMEM containing 10% FBS for 1 hour and then minced in the presence of DNase I. The suspended cells were serially filtered, and then negatively selected for CD45 (CELLection Biotin Binder Kit) using magnetic beads bound to anti-CD45 antibody. The cell suspension was stained with Pacific Blue-conjugated primary antibody against CD45 (Life Technologies, catalog MCD 4528), APC-Epcam (eBioscience), and Cell Viability Dye eFluor 780. After a final wash, cells were suspended in PBS, analyzed by flow cytometry, and sorted on a BD Aria cell sorter for Epcam-positive cells.
SA-β-gal assay. To measure SA-β-gal (35) , perfused lungs were processed to obtain cellular suspensions followed by depletion of CD45-positive cells (CELLection Biotin Binder Kit) using a biotinylated CD45 antibody. The CD45-depleted cell suspension was pretreated with bafilomycin A1 followed by treatment with 5-dodecanoylaminofluorescein di-β-D-galactopyranoside (C12FDG). Cells were then incubated with Pacific Blue-conjugated rat anti-mouse CD45, APC-Epcam, and Cell Viability Dye eFluor 780, washed, and analyzed by flow cytometry with FlowJO software (Version X). To visualize senescent cells by cytochemistry, 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal) was used as a substrate on lung cryosections (36) .
Extravascular lung water measurement (EVLW). EVLW was measured by gravimetry as described (22) . Mouse lungs were harvested from the thoracic cavity and homogenized after adding a fixed quantity of water. Lung homogenate was weighed immediately and then dried overnight at 65°C in an oven to record the dry weight. Hemoglobin in the lung homogenate and in the blood was measured to calculate the weight of blood in the lungs. The difference between blood water and lung water provided the EVLW value.
Isolation of pulmonary fibroblasts. Pulmonary fibroblasts were isolated from Col1a2-Cre TRF1 fl/fl mice and TRF1 fl/fl mice by digesting lungs in 10 mg/ml Dispase suspended in DMEM containing 10% FBS for 1 hour at 37°C, and then minced in the presence of DNase I. The cell lysate was centrifuged at 800 g for 10 minutes at 4°C. The cell pellet was resuspended in DMEM medium containing 10% FBS and cultured for 4 days. Nonadherent cells were rinsed and adherent fibroblasts were cultured for 3 more days prior to harvest for analysis.
Influenza virus infection. Anesthetized mice were inoculated intranasally with 5,000 PFU of purified human influenza A/PR/8/34 (H1N1) virus (Advanced Biotechnologies, catalog 10-210-500) suspended in 25 μl sterile PBS. The mice were recovered and monitored 3 times daily and their survival recorded. Moribund mice were euthanized by CO 2 inhalation and cervical dislocation.
Preparation of cell lysates and immunoblotting. Cells were washed with ice-cold PBS and then lysed in RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, Nonidet P-40, 0.25 % sodium deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulfonylfluoride, 1 mM sodium orthovanadate, 1 mM sodium fluoride) containing protease and phosphatase inhibitor cocktail (Sigma-Aldrich). Protein concentration was measured in the lysate using a Pierce BCA protein assay kit (Thermo Fisher Scientific). Equal volumes of sample supernatants were adjusted to 1 mg/ml protein, dissolved in 4× SDS sample buffer, and denatured by boiling for 5 minutes. Sample proteins were resolved in 4%-15% SDS-PAGE gradient gels (Bio-Rad), transferred onto nitrocellulose membranes, blocked in TBS buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.4) containing 5% milk and incubated with primary (TRF1 diluted 1:1,000; β-actin diluted 1:2,500) and secondary (goat anti-mouse IgG-HRP) antibodies. The proteins were detected by an ECL kit (Thermo Fisher Scientific), scanned, and analyzed by ImageJ software (NIH).
Statistics. Statistical analysis was performed using 2-tailed Student's t test. Welch's correction was applied for analysis of unpaired groups. Differences in survival were analyzed by log-rank test. Analysis between multiple groups was performed by 1-way ANOVA with Tukey's post-hoc test. P values less than 0.05 were considered significant. Data are represented as the mean ± SEM.
Study approval. TRF1 fl/fl mice were purchased from Jackson Laboratories, Col1a2-Cre/ERT mice were provided by Steve Nishimura (UCSF), and SPC-Cre ER T2 rtTA mice were provided by Hal Chapman (UCSF). Mice were bred and housed in pathogen-free conditions in accordance with the guidelines of Laboratory Animal Resource Center (LARC). All animal procedures were carried out using protocols approved by the Institutional Animal Care and Use Committee, UCSF.
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